Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gill Adams

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Protein Engineering, Design & Selection : PEDS|February 15, 2005
Latent cytokines: development of novel cleavage sites and kinetic analysis of their differential sensitivity to MMP-1 and MMP-3Sandrine Vessillier, Gill Adams, Yuti Chernajovsky
Discovery Medicine|August 14, 2010
Targeting therapeutic molecules to sites of diseaseYuti Chernajovsky, Sandrine Vessillier, Gill Adams
Journal of Biotechnology|July 28, 2012
Increased disulphide dimer formation of latent associated peptide fusions of TGF-β by addition of L-cystineLisa M Mullen, Gill Adams, Yuti Chernajovsky
The British Journal of Ophthalmology|February 28, 2012
The effect on quality of life of long-term botulinum toxin A injections to maintain ocular alignment in adult patients with strabismusJoanne Hancox, Shanel Sharma, Kelly MacKenzie, et al.
Nature Biotechnology|October 7, 2003
Targeting cytokines to inflammation sitesGill Adams, Sandrine Vessillier, Hanna Dreja, et al.
Strabismus|December 17, 2009
Alternate day exotropiaEmma Dawson, Gill Adams, Lak Mengher, et al.
Trends in Molecular Medicine|June 5, 2004
Methods for targeting biologicals to specific disease sitesAhuva Nissim, Yarunnessa Gofur, Sandrine Vessillier, et al.
The Cochrane Database of Systematic Reviews|May 13, 2016
Psychosocial interventions for improving quality of life outcomes in adults undergoing strabismus surgeryKelly MacKenzie, Joanne Hancox, Hayley McBain, et al.
Annals of the Rheumatic Diseases|October 15, 2011
Molecular engineering of short half-life small peptides (VIP, αMSH and γ₃MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeuticsSandrine Vessillier, Gill Adams, Trinidad Montero-Melendez, et al.
Eye (London, England)|April 21, 2021
The UK practice of Anti-VEGF therapy for treatment of retinopathy of prematurityShahanaz B Ahmed, Aisling Higham, Alan Mulvihill, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Protein Engineering, Design & Selection : PEDS|February 15, 2005
Latent cytokines: development of novel cleavage sites and kinetic analysis of their differential sensitivity to MMP-1 and MMP-3Sandrine Vessillier, Gill Adams, Yuti Chernajovsky
Discovery Medicine|August 14, 2010
Targeting therapeutic molecules to sites of diseaseYuti Chernajovsky, Sandrine Vessillier, Gill Adams
Journal of Biotechnology|July 28, 2012
Increased disulphide dimer formation of latent associated peptide fusions of TGF-β by addition of L-cystineLisa M Mullen, Gill Adams, Yuti Chernajovsky
The British Journal of Ophthalmology|February 28, 2012
The effect on quality of life of long-term botulinum toxin A injections to maintain ocular alignment in adult patients with strabismusJoanne Hancox, Shanel Sharma, Kelly MacKenzie, et al.
Nature Biotechnology|October 7, 2003
Targeting cytokines to inflammation sitesGill Adams, Sandrine Vessillier, Hanna Dreja, et al.
Strabismus|December 17, 2009
Alternate day exotropiaEmma Dawson, Gill Adams, Lak Mengher, et al.
Trends in Molecular Medicine|June 5, 2004
Methods for targeting biologicals to specific disease sitesAhuva Nissim, Yarunnessa Gofur, Sandrine Vessillier, et al.
The Cochrane Database of Systematic Reviews|May 13, 2016
Psychosocial interventions for improving quality of life outcomes in adults undergoing strabismus surgeryKelly MacKenzie, Joanne Hancox, Hayley McBain, et al.
Annals of the Rheumatic Diseases|October 15, 2011
Molecular engineering of short half-life small peptides (VIP, αMSH and γ₃MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeuticsSandrine Vessillier, Gill Adams, Trinidad Montero-Melendez, et al.
Eye (London, England)|April 21, 2021
The UK practice of Anti-VEGF therapy for treatment of retinopathy of prematurityShahanaz B Ahmed, Aisling Higham, Alan Mulvihill, et al.
Pageof 2